New combo attack on rare bladder cancer shows promise in early trial
NCT ID NCT04383743
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 22 times
Summary
This pilot study tested whether giving a combination of immunotherapy (pembrolizumab) and chemotherapy before surgery could help people with rare types of muscle-invasive bladder cancer. 17 participants received the treatment to see if it could eliminate all signs of cancer at the time of surgery. The goal was to improve outcomes compared to chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.